keyword
MENU ▼
Read by QxMD icon Read
search

Tedizolide

keyword
https://www.readbyqxmd.com/read/27904526/new-agents-approved-for-treatment-of-acute-staphylococcal-skin-infections
#1
Jan Tatarkiewicz, Anna Staniszewska, Magdalena Bujalska-Zadrożny
Vancomycin has been a predominant treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections for decades. However, growing reservations about its efficacy led to an urgent need for new antibiotics effective against MRSA and other drug-resistant Staphylococcus aureus strains. This review covers three new anti-MRSA antibiotics that have been recently approved by the FDA: dalbavancin, oritavancin, and tedizolid. The mechanism of action, indications, antibacterial activity profile, microbial resistance, pharmacokinetics, clinical efficacy, adverse effects, interactions as well as available formulations and administration of each of these new antibiotics are described...
December 1, 2016: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/27890418/comparative-in-vitro-activity-of-oritavancin-and-other-agents-against-methicillin-susceptible-and-methicillin-resistant-staphylococcus-aureus
#2
Debora Sweeney, Dean L Shinabarger, Francis F Arhin, Adam Belley, Greg Moeck, Chris M Pillar
Methicillin-resistant Staphylococcus aureus (MRSA) infections constitute a threat to the public health due to their prevalence and associated mortality and morbidity. Several agents have been recently approved to treat MRSA skin infections including lipoglycopeptides (dalbavancin, oritavancin, and telavancin), ceftaroline, and tedizolid. This study compared the MIC, minimum bactericidal concentration (MBC), and time-kill of these agents alongside daptomycin, linezolid, and vancomycin against MRSA (n=15); meropenem, cefazolin, and nafcillin were also included against methicillin-susceptible S...
November 12, 2016: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/27889013/methicillin-resistant-staphylococcus-aureus-infections-a-review-of-the-currently-available-treatment-options
#3
REVIEW
S M Purrello, J Garau, E Giamarellos, T Mazzei, F Pea, A Soriano, S Stefani
This review is the result of discussions that took place at the 5th MRSA Working Group Consensus Meeting and explores the possible treatment options available for different types of infections due to methicillin-resistant Staphylococcus aureus (MRSA), focusing on those antibiotics that could represent a valid alternative to vancomycin. In fact, whilst vancomycin remains a viable option, its therapy is moving towards individualised dosing. Other drugs, such as the new lipoglycopeptides (oritavancin, dalbavancin and telavancin) and fifth-generation cephalosporins (ceftaroline and ceftobiprole), are showing good in vitro potency and in vivo efficacy, especially for patients infected with micro-organisms with higher vancomycin minimum inhibitory concentrations (MICs)...
December 2016: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/27873126/resistance-to-non-glycopeptide-agents-in-serious-staphylococcus-aureus-infections
#4
REVIEW
Kyle C Molina, Vanthida Huang
The role of vancomycin in the treatment of serious Staphylococcus aureus infections, both methicillin-susceptible and methicillin-resistant, is becoming increasingly ineffective due to increasing MIC and failure. The development of reduced vancomycin susceptibility by S. aureus to glycopeptides highlights the need for clinicians to reexamine the roles of non-glycopeptide therapy. As the use of these alternative non-glycopeptides antimicrobials increases, it will become pertinent to monitor the rates of resistance...
December 2016: Current Infectious Disease Reports
https://www.readbyqxmd.com/read/27866673/surveillance-of-tedizolid-activity-and-resistance-in-vitro-susceptibility-of-gram-positive-pathogens-collected-over-5-years-from-the-united-states-and-europe
#5
Mekki Bensaci, Daniel Sahm
In vitro activity of tedizolid and comparators against 11,231 Gram-positive clinical isolates from the United States (84 centers) and Europe (115 centers) were summarized as part of the Surveillance of Tedizolid Activity and Resistance program between 2009 and 2013. Susceptibility testing was performed according to Clinical Laboratory and Standards Institute (CLSI) guidelines. Minimum inhibitory concentration (MIC) interpretations were based on CLSI and European Committee on Antimicrobial Susceptibility Testing criteria...
October 8, 2016: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/27855069/activity-of-tedizolid-in-methicillin-resistant-staphylococcus-epidermidis-experimental-foreign-body-associated-osteomyelitis
#6
Kyung-Hwa Park, Kerryl E Greenwood-Quaintance, Audrey N Schuetz, Jayawant N Mandrekar, Robin Patel
We developed a rat model of methicillin-resistant Staphylococcus epidermidis (MRSE) foreign body-associated osteomyelitis and used it to compare tedizolid alone and in combination with rifampin, against rifampin alone, vancomycin plus rifampin, and vancomycin alone. A clinical strain of MRSE was inoculated into the proximal tibia and a stainless-steel wire with precolonized MRSE biofilm was implanted. Following a one-week infection period, 92 rats received either no treatment (n=17) or 14 days of intraperitoneal tedizolid (n=15), tedizolid plus rifampin (n=15), rifampin (n=15), vancomycin plus rifampin (n=15), or vancomycin (n=15)...
November 14, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27799200/comparative-in-vivo-efficacy-of-tedizolid-in-neutropenic-versus-immunocompetent-murine-streptococcus-pneumoniae-lung-infection-models
#7
Kamilia Abdelraouf, David P Nicolau
Given that tedizolid exhibits substantial lung penetration, we hypothesize that it could achieve good efficacy against Streptococcus pneumoniae lung infections. We evaluated the pharmacodynamics of tedizolid for treatment of S. pneumoniae lung infections and compared efficacy of tedizolid human-simulated epithelial lining fluid (ELF) exposures in immunocompetent and neutropenic murine lung infection models. ICR mice were rendered neutropenic via intraperitoneal cyclophosphamide injections, then inoculated intranasally with S...
October 31, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27769972/physical-compatibility-of-tedizolid-phosphate-with-selected-i-v-drugs-during-simulated-y-site-administration
#8
Islam Ghazi, Yukihiro Hamada, David P Nicolau
PURPOSE: The physical compatibility of commonly used agents that could be coadministered in the clinical setting with tedizolid phosphate during Y-site administration was evaluated. METHODS: Tedizolid phosphate vials were reconstituted to a final concentration of 0.8 mg/mL. All other drugs were prepared according to manufacturers' recommendations and diluted with 0.9% sodium chloride injection (where applicable) to the highest standard concentrations used clinically...
November 1, 2016: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27743684/-comparative-activity-of-tedizolid-against-clinical-isolates-of-linezolid-resistant-coagulase-negative-staphylococci-and-methicillin-resistant-staphylococcus-aureus
#9
Santiago Pérez-Parra, Alejandro Peña-Monje, Juan Luis Recio, Federico García-García
No abstract text is available yet for this article.
October 12, 2016: Enfermedades Infecciosas y Microbiología Clínica
https://www.readbyqxmd.com/read/27721280/in-vitro-activity-of-ceftaroline-a-novel-antibiotic-against-methicillin-resistant-staphylococcus-aureus
#10
Vaishali Gaikwad, Tejash Gohel, Shrijeet Panickar, Vijay Chincholkar, Santosh Mangalkar
INTRODUCTION: Staphylococcus is one of the most common causes of nosocomial infection, especially pneumonia, surgical site infections, blood stream infections, and continues to be a major cause of community-acquired infections. The emergence of penicillin resistance followed by the development and spread of strains resistant to the semisynthetic penicillins such as methicillin, oxacillin and nafcillin, macrolides, tetracycline, and aminoglycosides has made the treatment of staphylococcal infection a global challenge...
October 2016: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/27718751/tedizolid-in-skin-and-skin-structure-infections-brave-new-world
#11
P Panagopoulos, N Papanas, E Maltezos
No abstract text is available yet for this article.
October 10, 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27713022/the-underappreciated-in%C3%A2-vitro-activity-of-tedizolid-against-bacteroides-fragilis-species-including-strains-resistant-to-metronidazole-and-carbapenems
#12
Ellie J C Goldstein, Diane M Citron, Kerin L Tyrrell, Elisa S Leoncio, C Vreni Merriam
Because Bacteroides fragilis has the ability to develop mechanisms of resistance to almost all antibiotics, we studied the comparative in vitro activity of tedizolid against 124 Bacteroides group species clinical isolates, including carbapenem, metronidazole and piperacillin-tazobactam resistant strains. Tedizolid had an MIC90 of 2 μg/ml (range, 0.5-4 μg/ml) and was 1-4 times more active than linezolid that had an MIC90 of 8 μg/ml (range, 2-16 μg/ml). It was also active (MICs 0.5-2 μg/ml) against the 27 ertapenem, 2 metronidazole and 12 piperacillin-tazobactam resistant strains tested...
October 3, 2016: Anaerobe
https://www.readbyqxmd.com/read/27677280/in-vitro-activity-of-tedizolid-against-staphylococcus-aureus-and-streptococcus-pneumoniae-collected-in-2013-and-2014-from-sites-in-latin-american-countries-australia-new-zealand-and-china
#13
D J Biedenbach, S K Bouchillon, B Johnson, J Alder, D F Sahm
Tedizolid is an oxazolidinone with an antimicrobial in vitro potency advantage against Gram-positive bacterial pathogens compared to other currently marketed drugs in this class, including linezolid. Tedizolid was compared to linezolid when tested against Staphylococcus aureus and Streptococcus pneumoniae isolates collected from countries in Latin America and the Asia-Pacific. Isolates were tested by broth microdilution susceptibility methods against tedizolid, linezolid, and non-class comparators in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines...
December 2016: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/27645240/in-vitro-and-in-vivo-activities-of-a-bi-aryl-oxazolidinone-rbx-11760-against-gram-positive-bacteria
#14
Tarani Kanta Barman, Manoj Kumar, Tarun Mathur, Tridib Chaira, G Ramkumar, Vandana Kalia, Madhvi Rao, Manisha Pandya, Ajay Singh Yadav, Biswajit Das, Dilip J Upadhyay, Hamidullah, Rituraj Konwar, V Samuel Raj, Harpal Singh
RBx 11760, a bi-aryl oxazolidinone, was investigated for antibacterial activity against Gram-positive bacteria. The MIC90s of RBx 11760 and linezolid against Staphylococcus aureus were 2 and 4 mg/liter, against Staphylococcus epidermidis were 0.5 and 2 mg/liter, and against Enterococcus were 1 and 4 mg/liter, respectively. Similarly, against Streptococcus pneumoniae the MIC90s of RBx 11760 and linezolid were 0.5 and 2 mg/liter, respectively. In time-kill studies, RBx 11760, tedizolid, and linezolid exhibited bacteriostatic effect against all tested strains except S...
December 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27599998/in-vitro-activities-of-tedizolid-compared-with-other-antibiotics-against-gram-positive-pathogens-associated-with-hospital-acquired-pneumonia-hap-skin-and-soft-tissue-infection-ssti-and-bloodstream-infection-bsi-collected-from-hospitals-in-china
#15
Shuguang Li, Yu Guo, Chunjiang Zhao, Hongbin Chen, Bijie Hu, Yunzhuo Chu, Zhijie Zhang, Yunjian Hu, Zhiyong Liu, Yan Du, Qiaodi Gui, Ping Ji, Ji Zeng, Bin Cao, Quan Fu, Rong Zhang, Zhongxin Wang, Chao Zhuo, Xianju Feng, Wei Jia, Yan Jin, Xuesong Xu, Kang Liao, Yuxing Ni, Yunsong Yu, Xiuli Xu, Zhidong Hu, Jin-E Lei, Qing Yang, Hui Wang
To evaluate the in vitro antimicrobial activities of tedizolid, linezolid and other comparators against clinically significant Gram-positive cocci isolates from hospital-acquired pneumonia (HAP), skin and soft tissue infection (SSTI) and bloodstream infection (BSI), 2140 non-duplicate isolates (23.7% isolated from HAP, 46.8% from SSTI and 29.5% from BSI) were consecutively collected in 26 hospitals in 17 cities across China during 2014. These pathogens included 632 methicillin-resistant Staphylococcus aureus (MRSA), 867 methicillin-sensitive S...
September 2, 2016: Journal of Medical Microbiology
https://www.readbyqxmd.com/read/27550347/activity-of-tedizolid-in-methicillin-resistant-staphylococcus-aureus-experimental-foreign-body-associated-osteomyelitis
#16
Kyung-Hwa Park, Kerryl E Greenwood-Quaintance, Jayawant Mandrekar, Robin Patel
BACKGROUND: We compared tedizolid alone and with rifampin against rifampin and vancomycin plus rifampin in rat model of methicillin-resistant Staphylococcus aureus (MRSA) foreign body-associated osteomyelitis. METHODS: The study strain was a prosthetic joint infection-associated isolate. Steady-state pharmacokinetics for intraperitoneal administration of tedizolid, vancomycin, and rifampin were determined in uninfected rats. MRSA was inoculated into the proximal tibia, and a wire was implanted...
August 22, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27541932/biotransformation-of-fluorophenyl-pyridine-carboxylic-acids-by-the-model-fungus-cunninghamella-elegans
#17
William Palmer-Brown, Brian Dunne, Yannick Ortin, Mark A Fox, Graham Sandford, Cormac D Murphy
1. Fluorine plays a key role in the design of new drugs and recent FDA approvals included two fluorinated drugs, tedizolid phosphate and vorapaxar, both of which contain the fluorophenyl pyridyl moiety. 2. To investigate the likely phase I (oxidative) metabolic fate of this group, various fluorinated phenyl pyridine carboxylic acids were incubated with the fungus Cunninghamella elegans, which is an established model of mammalian drug metabolism. 3. (19)F NMR spectroscopy established the degree of biotransformation, which varied depending on the position of fluorine substitution, and GC-MS identified alcohols and hydroxylated carboxylic acids as metabolites...
August 19, 2016: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://www.readbyqxmd.com/read/27533787/tedizolid-and-linezolid-for-treatment-of-acute-bacterial-skin-and-skin-structure-infections-of-the-lower-extremity-versus-non-lower-extremity-pooled-analysis-of-two-phase-3-trials
#18
Warren S Joseph, Darren Culshaw, Steven Anuskiewicz, Carisa De Anda, Philippe Prokocimer
BACKGROUND: Tedizolid phosphate, the prodrug of the oxazolidinone tedizolid, has been approved in a number of countries, including the United States, those in the European Union, and Canada, for treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Two Phase 3 trials demonstrated the noninferior efficacy of tedizolid (200 mg once daily for 6 days) to linezolid (600 mg twice daily for 10 days) in patients with ABSSSI. Because of the challenges of treating lower-extremity ABSSSI, the efficacy and safety of tedizolid and linezolid for treating lower extremity versus non-lower extremity infections were compared...
August 17, 2016: Journal of the American Podiatric Medical Association
https://www.readbyqxmd.com/read/27530088/clinician-reported-lesion-measurements-in-skin-infection-trials-definitions-reliability-and-association-with-patient-reported-pain
#19
John H Powers, Anita F Das, Carisa De Anda, Philippe Prokocimer
OBJECTIVES: Outcome assessments as clinical trial endpoints should be well-defined, reliable, and reflect meaningful treatment benefits. For acute bacterial skin and skin structure infections (ABSSSI) trials, recent recommendations suggest a primary endpoint of reduction in skin lesion area. Objectives were: evaluate ABSSSI lesion area measurement reliability, evaluate impact of various lesion area definitions on treatment effect size, and explore relationships between lesion area and pain...
September 2016: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/27525679/tedizolid-susceptibility-in-linezolid-and-vancomycin-resistant-enterococcus-faecium-isolates
#20
E-M Klupp, A Both, C Belmar Campos, H Büttner, C König, M Christopeit, M Christner, M Aepfelbacher, H Rohde
Vancomycin-resistant enterococci (VRE) are of ever-increasing importance, most notably in high-risk patient populations. Therapy options are often limited for these isolates, and apart from tigecycline and daptomycin, oxazolidinone linezolid is frequently administered. The broad usage of linezolid, however, has driven the emergence of linezolid-resistant VRE strains (LR-VRE), further shortening therapeutic options. Second-generation oxazolidinone tedizolid has the advantage of being active against a specific subset of LR-VRE, i...
December 2016: European Journal of Clinical Microbiology & Infectious Diseases
keyword
keyword
15432
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"